Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

Canon Medical Reinforces Commitment to AI Innovation With New Altivity Brand

Canon Medical has today announced the launch of Altivity, a new AI innovation brand, that consolidates machine learning and deep learning technologies to deliver uncompromised quality and value across the entire care pathway.

Canon Medical has been steadily redefining the role of AI in healthcare, starting with its Advanced intelligent Clear-IQ Engine (AiCE). Initially developed for CT, this denoising deep learning technology was soon deployed across MRI and PET/molecular imaging to help speed up scan times and improve image quality. Next came the launch of Automation Platform and AUTOStroke solution, both of which were designed to enhance clinical confidence and streamline workflows with the power of deep learning technology.

More recently, Canon Medical has transformed the ultrasound space with AI innovations*, that revolutionize clinical workflows. One of the most time-consuming aspects of an ultrasound exam is the care that must be taken to ensure serial measurements are done in a standardized and highly reproducible way. By leveraging the power of AI, Canon Medical has been able to automate these routine tasks to increase clinical productivity and reporting accuracy.

Under the promise of Intelligent healthcare made easy, Altivity enables:

  • Informed healthcare
    Altivity is here to help enhance clinical confidence with high-quality images and applications that help make informed decisions in real time.
  • Fast, tailored care
    Altivity has been created with patients in mind, to deliver the fast and accurate results they need for a more personalized treatment approach.
  • Efficient workflows
    Altivity helps create simple, streamlined AI-driven workflows that optimize resource deployment and ensure your teams have the insights they need to work smarter every day.

Toshio Takiguchi, President and CEO of Canon Medical, says of the launch, “We are passionate about the development of intelligent imaging solutions that reflect the changing medical landscape. With Altivity, we are strengthening our focus to help clinicians leverage their data and transform it into essential insight that improves outcomes for everyone.”

Naoki Sasaki, Head of Research and Development, echoed these sentiments by saying that “Canon Medical’s commitment to continued research and development has resulted in products that are establishing new standards in the area of AI in medicine and healthcare.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Ariceum Therapeutics’ Targeted Radiopharmaceutical 177Lu-satoreotide Exhibits Promising Clinical Response and Good Tolerability Profile in Patients with Advanced Neuroendocrine Tumours

Satoreotide combines Ariceum’s proprietary peptide satoreotide - a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SSTR2) - with the radioactive isotope ‘payload’ 177Lutetium. SSTR2 is a cell surface protein often overexpressed in certain cancers, including NETs and small cell lung cancer (SCLC).

New Hot Start Isothermal Mixes Boost Sensitivity, Specificity, and Speed of DNA Target Detection

Isothermal mixes are important in a range of isothermal amplification applications, including whole genome amplification, point-of-care assay development and testing, and strand displacement amplification for synthetic biology. However, a common issue with isothermal mixes is non-specific amplification — where primers bind to unintended DNA targets — because amplification often takes place at a fixed temperature which may favour non-specific primer interactions, contrary to PCR. Isothermal mixes can also lead to primer dimer formation, where primers associate with each other and are extended by the polymerase.

Branded Legacy Invests Heavily in Innovation and Growth with $540,000 Expansion

This strategic initiative underscores Branded Legacy's unwavering commitment to innovation, quality, and customer satisfaction. The expansion project is set to infuse over $500,000 worth of inventory into the company, reinforcing its position as a leader in the market.

Cue Biopharma Completes Patient Enrollment in Ph1b Head & Neck Cancer Trial

“Completing the enrollment of the recommended phase 2 dose patient expansion cohort is an important milestone as the data from this trial guides further development plans and associated discussions with the Food and Drug Administration (FDA),” said Daniel Passeri, chief executive officer of Cue Biopharma.

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Michelle Fraser, head of cell and gene therapy at Revvity, underscores the importance of providing broad access to this technology: "Base editing has been extensively demonstrated in numerous studies to safely and precisely control the correction of single base changes at multiple target sites, simultaneously. This streamlined approach simplifies complex multi-gene editing, holding great promise for the development of new cell therapies targeting rare inherited genetic diseases, cancer, and in the creation of universal donor cells as the foundation of allogeneic cell therapies."

By using this website you agree to accept Medical Device News Magazine Privacy Policy